Dr. Michael Kasper, MD
What this data tells you about Dr. Kasper
Dr. Michael Kasper is a medical oncology in Austin, TX, with 19 years in practice. Based on federal Medicare data, Dr. Kasper performed 62,447 Medicare services across 4,186 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kasper received a total of $132 from 6 pharmaceutical and/or device companies across 8 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kasper is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 10,300 | $42 | $136 |
| Anti-nausea injection (fosaprepitant) | 9,300 | $0 | $5 |
| Paclitaxel chemotherapy injection | 8,724 | $0 | $8 |
| Iron sucrose injection (Venofer) | 8,500 | $0 | $2 |
| Contrast dye for imaging (iodine-based) | 7,450 | $0 | $3 |
| Anti-nausea injection (aprepitant) | 2,210 | $1 | $8 |
| Denosumab injection (Prolia/Xgeva) | 1,920 | $18 | $66 |
| Dexamethasone injection (steroid) | 1,514 | $0 | $1 |
| Blood draw (venipuncture) | 1,400 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,376 | $8 | $36 |
| Comprehensive metabolic blood panel | 1,037 | $10 | $64 |
| Anti-nausea injection (Aloxi/palonosetron) | 970 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 740 | $0 | $24 |
| Immunoglobulin level test | 613 | $9 | $56 |
| Office visit, established patient (20-29 min) | 527 | $64 | $250 |
| Measurement of immunoglobulin light chains | 482 | $17 | $60 |
| Injection, carboplatin, 50 mg | 360 | $2 | $300 |
| Injection of additional new drug or substance into vein | 342 | $12 | $108 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 288 | $85 | $1,348 |
| Administration of chemotherapy into vein, 1 hour or less | 262 | $101 | $707 |
| Ferritin level test (iron stores) | 246 | $13 | $60 |
| Iron level test | 245 | $6 | $27 |
| Iron binding capacity test | 245 | $9 | $35 |
| Office visit, established patient (30-39 min) | 228 | $94 | $368 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 224 | $3 | $373 |
| Reticulated (young) platelet measurement | 187 | $35 | $143 |
| Injection, zoledronic acid, 1 mg | 142 | $6 | $431 |
| Injection, magnesium sulfate, per 500 mg | 132 | $1 | $6 |
| Microscopic examination for white blood cells with manual cell count | 127 | $4 | $22 |
| Complete blood count (CBC), automated | 127 | $6 | $34 |
| Protein measurement, serum | 126 | $11 | $99 |
| Immunologic analysis technique on serum | 126 | $29 | $108 |
| Immunologic analysis technique on serum (immunofixation) | 126 | $22 | $160 |
| Administration of chemotherapy into vein, each additional hour | 126 | $22 | $161 |
| Administration of additional new drug or substance into vein, 1 hour or less | 118 | $48 | $344 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 112 | $21 | $157 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 104 | $301 | $2,762 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 98 | $49 | $313 |
| Injection, diphenhydramine hcl, up to 50 mg | 85 | $1 | $7 |
| Drug injection, under skin or into muscle | 76 | $11 | $96 |
| Carcinoembryonic antigen (cea) protein level | 73 | $19 | $99 |
| Lactate dehydrogenase (enzyme) level | 73 | $6 | $31 |
| Thyroid stimulating hormone (TSH) test | 73 | $16 | $80 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 71 | $14 | $94 |
| Ct scan of chest with contrast | 62 | $48 | $821 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 62 | $59 | $211 |
| Infusion, normal saline solution , 1000 cc | 58 | $2 | $19 |
| CT scan of abdomen and pelvis with contrast | 57 | $181 | $1,067 |
| PSA test (prostate cancer screening) | 51 | $18 | $94 |
| Unclassified drugs | 47 | $1 | $8 |
| Magnesium level test | 45 | $7 | $29 |
| Red blood count automated, with additional calculations | 42 | $5 | $26 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 40 | $16 | $100 |
| New patient office visit (45-59 min) | 36 | $127 | $565 |
| Irrigation of implanted venous access drug delivery device | 32 | $19 | $114 |
| Administration of additional new drug or substance into vein using push technique | 30 | $46 | $289 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 26 | $25 | $145 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 26 | $87 | $657 |
| Infusion into a vein for hydration, each additional hour | 25 | $10 | $75 |
| Application of on-body injector for under skin injection | 23 | $14 | $96 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 22 | $1,229 | $4,802 |
| Office visit, established patient, complex (40-54 min) | 22 | $143 | $496 |
| Folic acid level test | 21 | $14 | $73 |
| Vitamin B-12 level test | 20 | $15 | $76 |
| Hospital follow-up visit, low complexity | 20 | $39 | $135 |
| Stool analysis for blood to screen for colon tumors | 19 | $4 | $24 |
| Infusion into a vein for hydration, 31-60 minutes | 16 | $27 | $256 |
| CT scan of chest, without contrast | 15 | $41 | $686 |
| New patient office visit (30-44 min) | 14 | $72 | $372 |
| Urinalysis with microscopic exam | 11 | $3 | $28 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
The majority of payments (59%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in medical oncology and does not inherently indicate bias, but patients may wish to be aware.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kasper is a mixed practice specialist, with above-average Medicare volume (top 16% in TX), and speaking/promotional industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kasper experienced with pembrolizumab injection (keytruda)?
Does Dr. Kasper receive payments from pharmaceutical companies?
How do Dr. Kasper's costs compare to other medical oncologys in Austin?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology